MNG602
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.674
- OXIDATIVE_PHOSPHORYLATION+0.579
- MYC_TARGETS_V1+0.543
- INTERFERON_ALPHA_RESPONSE+0.492
- DNA_REPAIR+0.359
- E2F_TARGETS+0.326
- UNFOLDED_PROTEIN_RESPONSE+0.306
- MTORC1_SIGNALING+0.283
- INTERFERON_GAMMA_RESPONSE+0.269
- ALLOGRAFT_REJECTION+0.247
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.396
- HEDGEHOG_SIGNALING-0.388
- HYPOXIA-0.387
- TNFA_SIGNALING_VIA_NFKB-0.364
- UV_RESPONSE_DN-0.340
- TGF_BETA_SIGNALING-0.334
- APICAL_SURFACE-0.308
- MITOTIC_SPINDLE-0.300
- MYOGENESIS-0.279
- PANCREAS_BETA_CELLS-0.271
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | cdef9a7f-9daa-4a33-b196-08a12a2ed203 | — | — | 0.882 |
| 2 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.857 |
| 3 | MNG171 | — | — | 0.848 |
| 4 | MNG277 | — | — | 0.846 |
| 5 | SRR8518323 | — | E | 0.834 |
| 6 | MNG510 | — | — | 0.831 |
| 7 | SRR11296765 | — | — | 0.819 |
| 8 | TCGA-A8-A09M-01A-11R-A00Z-07 | — | B | 0.819 |
| 9 | TCGA-CN-A642-01A-12R-A30B-07 | — | — | 0.813 |
| 10 | SRR27320678 | — | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.674 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.579 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.543 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.492 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.359 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.326 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.306 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.283 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.269 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.247 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.229 | Inavolisib | — uncovered |
| PEROXISOME | 0.219 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.212 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.169 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.149 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.123 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.113 | Inavolisib | — uncovered |
| COMPLEMENT | 0.043 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.035 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.032 | Inavolisib | — uncovered |